VivaZome Therapeutics is pleased to share that CEO, Xenia Sango, was an invited chair and speaker at the 12th Annual Biologics Manufacturing Asia Conference 2025, held at the Sands Expo & Convention Centre in Singapore. Recognised as Asia’s #1 bioprocessing event, the conference brought together over 1,300 attendees from more than 500 companies across the biologics and advanced therapeutics sectors.

Xenia presented on “Optimizing Biologics Production: Strategies for Tech Transfer, Scaling Up, Collaboration, and Compliance,” where she highlighted VivaZome’s innovative approach to manufacturing extracellular vesicle (EV)-based therapeutics for neuroinflammatory conditions, including traumatic brain injury and stroke.

The session showcased VivaZome’s in-house capabilities in EV process development, analytical characterisation, and regulatory-aligned scale-up, all critical elements in accelerating EV therapies from research to the clinic.